Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks
Stock Research Monitor: HRTX, IMNP, and PRGO
LONDON, UK / ACCESSWIRE / June 1, 2018/ If you want a free Stock Review on JNJ sign up now at www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Perrigo Co. PLC (NYSE: PRGO). These companies are part of the Healthcare sector, which provides goods or services relating to medicine or health care. The sector includes pharmaceuticals, health maintenance organizations, hospital management firms, and medical device manufacturers. All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Heron Therapeutics
San Diego, California headquartered Heron Therapeutics Inc.'s shares gained slightly by 0.46%, closing Thursday's trading session at $32.60. The stock recorded a trading volume of 572,334 shares. The Company's shares have advanced 3.33% in the last month, 57.11% over the previous three months, and 143.28% over the past year. The stock is trading 8.46% above its 50-day moving average and 54.19% above its 200-day moving average. Additionally, shares of Heron Therapeutics, which engages in developing medicines to address unmet medical needs, have a Relative Strength Index (RSI) of 59.41.
On May 29th, 2018, Heron Therapeutics announced that Barry D. Quart, Pharm.D., CEO, will present at the Jefferies 2018 Healthcare Conference on June 05th, 2018, at 2:00 p.m. EDT at the Grand Hyatt New York Hotel. A live webcast of this presentation will be available under the Investor Resources section of the Company's website. Get the full research report on HRTX for free by clicking below at:
www.wallstequities.com/registration/?symbol=HRTX
Immune Pharmaceuticals
On Thursday, shares in Englewood Cliffs, New Jersey headquartered Immune Pharmaceuticals Inc. recorded a trading volume of 304,686 shares. The stock rose slightly by 0.74%, ending the day at $0.23. The Company's shares are trading below their 50-day moving average by 28.63%. Furthermore, shares of Immune Pharma, which develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology, have an RSI of 33.67.
On May 23rd, 2018, Immune Pharma provided an update on its pipeline. Elliot Maza, President and CEO, commented:“We completed enrollment in our phase 2a bullous pemphigoid trial in the last quarter and all study visits have been completed. We believe the positive data from this study are strongly supportive of our plans to commence a pivotal phase 2/3 study next year. Also, we continue to advance our phase 2 proof-of-concept ulcerative colitis study with the goal of completing enrollment next quarter.” IMN's complimentary research coverage is a few simple steps away at:
www.wallstequities.com/registration/?symbol=IMNP
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock finished the day 1.12% lower at $119.62. A total volume of 10.27 million shares was traded, which was above their three months average volume of 6.75 million shares. The Company's shares are trading below their 50-day moving average by 5.40%. Additionally, shares of the Company, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 35.11.
On May 29th, 2018, Johnson & Johnson announced that it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on June 12th, 2018, at the Terranea Resort in Rancho Palos Verdes, California. Tom Cavanaugh, President, Oncology, Janssen Pharmaceuticals, and Scott White, President, Immunology, will represent the Company in a session scheduled at 9:20 a.m. PT that day. A webcast will be available on the Company's investor website. Register for your free research report on JNJ at:
www.wallstequities.com/registration/?symbol=JNJ
Perrigo
Shares in Dublin, Ireland headquartered Perrigo Co. PLC ended yesterday's session 3.66% lower at $73.16. The stock recorded a trading volume of 1.79 million shares, which was above their three months average volume of 1.15 million shares. The Company's shares have advanced 0.43% over the past year. The stock is trading 7.52% below its 50-day moving average. Moreover, shares of Perrigo, which manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide, have an RSI of 37.60.
On May 30th, 2018, Perrigo announced that Ron Winowiecki, CFO, will present at the Jefferies 2018 Healthcare Conference on June 05th, 2018, at 8:30 a.m. EST. Wall St. Equities' downloadable research report on PRGO available at:
www.wallstequities.com/registration/?symbol=PRGO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
